biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker BEAM. Primary therapeutic focus areas include Sleep, T-Cell Acute Lymphoblastic Leukemia/Lymphoma, Sickle Cell D
Cambridge, USA HQ
2017 Founded
573 Employees
Public company Type
BEAM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
BEAM-302
Phase 2 · small molecule · Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease is a Phase 2 program (small_molecule) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code BTX-302-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Beam Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
- Status
- active
- Trials
- 1